KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)DivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Other Working Capital Changes (2020 - 2025)

Historic Other Working Capital Changes for Recursion Pharmaceuticals (RXRX) over the last 6 years, with Q3 2025 value amounting to -$3.5 million.

  • Recursion Pharmaceuticals' Other Working Capital Changes fell 19009.45% to -$3.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$39.4 million, marking a year-over-year decrease of 3107.01%. This contributed to the annual value of -$28.0 million for FY2024, which is 3174.12% up from last year.
  • Recursion Pharmaceuticals' Other Working Capital Changes amounted to -$3.5 million in Q3 2025, which was down 19009.45% from -$3.1 million recorded in Q2 2025.
  • In the past 5 years, Recursion Pharmaceuticals' Other Working Capital Changes ranged from a high of $144.7 million in Q1 2022 and a low of -$27.1 million during Q1 2025
  • Its 5-year average for Other Working Capital Changes is -$135210.5, with a median of -$7.7 million in 2023.
  • In the last 5 years, Recursion Pharmaceuticals' Other Working Capital Changes plummeted by 119052.92% in 2021 and then surged by 501310.95% in 2022.
  • Quarter analysis of 5 years shows Recursion Pharmaceuticals' Other Working Capital Changes stood at -$2.5 million in 2021, then plummeted by 447.0% to -$13.7 million in 2022, then surged by 43.58% to -$7.7 million in 2023, then rose by 26.59% to -$5.7 million in 2024, then surged by 37.69% to -$3.5 million in 2025.
  • Its Other Working Capital Changes was -$3.5 million in Q3 2025, compared to -$3.1 million in Q2 2025 and -$27.1 million in Q1 2025.